Comparison of the Efficacy of Dipeptidylpeptidase-4 Inhibitors Between Asian and Non-Asian Populations

Yeong Gi Kim; Young Min Cho

doi:10.4093/jkd.2013.14.3.133

Journal List > J Korean Diabetes > v.14(3) > 1054875

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim and Cho: Comparison of the Efficacy of Dipeptidylpeptidase-4 Inhibitors Between Asian and Non-Asian Populations

Focused Issue

J Korean Diabetes 2013;14(3):133-137.

Published online: 10 January 2013

DOI: https://doi.org/10.4093/jkd.2013.14.3.133

Comparison of the Efficacy of Dipeptidylpeptidase-4 Inhibitors Between Asian and Non-Asian Populations

Yeong Gi Kim, Young Min Cho

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Type 2 diabetes is different between Asian and non-Asian populations. Compared with their Caucasian counterparts, Asian patients with type 2 diabetes have the characteristics of lower body mass index, lower insulin secretory response, and a lower degree of insulin resistance. Furthermore, a recent study revealed that the incretin effect is not decreased in Korean patients with type 2 diabetes compared with normal glucose tolerance. The HbA1c lowering efficacy of dipeptidylpeptidase-4 inhibitors, which enhances active incretin hormones, is greater in Asian people than in non-Asian people, which could be ascribed to their lower body mass indexes. Therefore, doctors should take these differing characteristics of type 2 diabetes in Asian patients into account for customized anti-diabetes therapy.

Keywords: Dipeptidylpeptidase-4 inhibitor, Type 2 diabetes mellitus, Asian population, Body mass index

References

1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368:1696–705.

2. Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther. 2012; 135:247–78.

3. Cho YM, Kieffer TJ. K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Vitam Horm. 2010; 84:111–50.

4. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986; 63:492–8.

5. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2011; 96:737–45.

6. Knop FK, Vilsboll T, Hojberg PV, Larsen S, Madsbad S, Volund A, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007; 56:1951–9.

7. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91:301–7.

8. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995; 136:3585–96.

9. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and metaanalysis. Diabetologia. 2013; 56:696–708.

10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35(Suppl 1):S64–71.

11. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004; 66(Suppl 1):S37–43.

12. Kim YI, Choi CS, Kim SW, Kim HK, Kim CH, Park JY, Hong SK, Lee KU. Changes in serum true insulin and C-peptide levels during oral glucose tolerance test in Koreans with glucose intolerance. J Korean Diabetes Assoc. 1998; 22:192–8.

13. STripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000; 49:975–80.

14. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006; 368:1681–8.

15. Lear SA, Humphries KH, Kohli S, Chockalingam A, Frohlich JJ, Birmingham CL. Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). Am J Clin Nutr. 2007; 86:353–9.

16. Park YW, Allison DB, Heymsfield SB, Gallagher D. Larger amounts of visceral adipose tissue in Asian Americans. Obes Res. 2001; 9:381–7.

17. Chiu KC, Cohan P, Lee NP, Chuang LM. Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care. 2000; 23:1353–8.

18. Oh TJ, Kim MY, Shin JY, Lee JC, Kim S, Park KS, Cho YM. The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes. Clin Endocrinol (Oxf). 2013 Feb 13. [Epub].http://dx.doi.org/10.1111/cen.12167.

19. Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and metaanalysis. Diabetes Care. 2013; 36:1789–96.

20. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007; 30:217–23.

21. VHu P, Yin Q, Deckert F, Jiang J, Liu D, Kjems L, Dole WP, He YL. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol. 2009; 49:39–49.

22. Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, Suetsugu M, Takebayashi K, Shibazaki M, Haruki K, Morita K, Inukai T. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res. 2012; 159:25–31.

Fig. 1.

Body mass index threshold hypothesis for the efficacy of dipeptidyl peptidase-4 inhibitors.

TOOLS

Similar articles